Latest News and Press Releases

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of...

Heildartekjur á árinu 2024 voru 492 milljónir dollara, sem er 427% aukning frá fyrra áriSölutekjur á árinu 2023 voru 273 milljónir dollara, sem er 462% aukning frá fyrra áriAðlöguð EBITDA framlegð var...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in...

Alvotech (NASDAQ: ALVO) tilkynnti í dag í samstarfi við bandaríska lyfjafyrirtækið Kashiv Biosciences og Advanz Pharma, alþjóðlegt lyfjafyrirtæki með höfuðstöðvar í Bretlandi, að Lyfjastofnun...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully...

REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of...

Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market

Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hafi keypt þróunarstarfsemi sænska líftæknifyrirtækisins Xbrane Biopharma AB (“Xbrane”). Með kaupunum eykur Alvotech afkastagetu sína í þróun...